Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 15, 2010
Last updated: July 24, 2010
Last verified: July 2010

RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping anticancer drugs near the tumor. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether chemoembolization is more effective with or without sunitinib malate in treating patients with liver cancer.

PURPOSE: This randomized phase II/III trial is studying the side effects of chemoembolization of the liver and to see how well in works when given together with or without sunitinib malate in treating patients with liver cancer.

Condition Intervention Phase
Liver Cancer
Drug: sunitinib malate
Procedure: quality-of-life assessment
Procedure: transarterial chemoembolization
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Unacceptable bleeding or hepatic failure at 10 weeks post-treatment [ Designated as safety issue: Yes ]
  • Overall survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor stabilization rate [ Designated as safety issue: No ]
  • Safety [ Designated as safety issue: Yes ]
  • Disease-free survival [ Designated as safety issue: No ]
  • Relapse-free survival [ Designated as safety issue: No ]
  • Quality of life [ Designated as safety issue: No ]
  • Overall survival rate at 2 years [ Designated as safety issue: No ]

Estimated Enrollment: 190
Study Start Date: July 2010
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Detailed Description:



  • To evaluate unacceptable bleeding or hepatic failure at 10 weeks post-treatment in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization in combination with sunitinib malate versus transarterial chemoembolization alone.
  • To evaluate the overall survival of these patients.


  • To evaluate the tumor stabilization rate in these patients.
  • To evaluate the safety of this regimen in these patients.
  • To evaluate the disease-free survival of these patients.
  • To evaluate the relapse-free survival of these patients.
  • To evaluate the quality of life of these patients.
  • To evaluate the overall survival rate at 2 years of these patients.

OUTLINE: This is a multicenter study.

Pilot: Patients receive oral sunitinib malate once daily on days 1-28. Beginning 7-10 days later, patients undergo 1-3 courses of transarterial chemoembolization (TACE). Treatment repeats every 6 weeks for 1 year.

Randomization: Patients are stratified according to main tumor diameter (< 5 cm vs ≥ 5 cm), nodular involvement (uninodular vs multinodular), and center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive sunitinib malate and TACE as in the pilot phase.
  • Arm II: Patients receive oral placebo once daily on days 1-28 and TACE as in the pilot phase.

Quality of life is assessed periodically.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed hepatocellular carcinoma or liver tumor responding to the Barcelona criteria
  • Child-Pugh score of 5-6 (Class A)
  • Tumor suitable for transarterial chemoembolization (one or more planned courses allowed)
  • Tumor not suitable for surgical resection
  • No extrahepatic metastases, including cerebral metastases


  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Hemoglobin ≥ 10 g/dL
  • PT ≥ 50%
  • Creatinine ≤ 120 μmol/L
  • Bilirubin normal
  • ALT/AST ≤ 3.5 times upper limit of normal (ULN)
  • Alkaline phosphatases ≤ 4 times ULN
  • Fibrinogen ≥ 1.5 g/L
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No portal vein thrombosis
  • Able to comply with scheduled follow-up and management of toxicity
  • No uncontrolled hypertension or requiring ≥ 2 classes of antihypertensive drugs
  • No concomitant disease or uncontrolled severe disease
  • No contraindications to the vascular occlusion procedure
  • No prior or concurrent malignancy within the past 5 years, except adequately treated cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin
  • No psychiatric disability or social, family, or geographic reason for which the patient may not be followed regularly


  • At least 7 days since prior CYP3A4 inhibitors or inducers
  • At least 3 months since prior radiofrequency ablation
  • No prior chemotherapy
  • No prior sunitinib, sorafenib, or any other inhibitors of angiogenesis
  • No concurrent participation in another trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01164202

Centre Hospital Universitaire Hop Huriez Recruiting
Lille, France, 59037
Contact: Contact Person    33-3-2044-5461   
Hopital Tenon Recruiting
Paris, France, 75970
Contact: Contact Person    33-1-5601-6404   
Institut Gustave Roussy Recruiting
Villejuif, France, F-94805
Contact: Contact Person    33-1-4211-4339      
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Principal Investigator: Mohamed Hebbar, MD Centre Hospital Universitaire Hop Huriez
  More Information

No publications provided Identifier: NCT01164202     History of Changes
Other Study ID Numbers: CDR0000681319  FFCD-PRODIGE-16  FFCD-0905  EUDRACT-2009-017064-16  EU-21050 
Study First Received: July 15, 2010
Last Updated: July 24, 2010
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
adult primary hepatocellular carcinoma
localized unresectable adult primary liver cancer
advanced adult primary liver cancer

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 10, 2016